June 10-13, 2023Boston, United States

The ACSMEDI|EFMC Medicinal Chemistry Frontiers is co-organised as a collaboration between the ACS (American Chemical Society) MEDI (Division of Medicinal Chemistry) and the EFMC (European Federation for Medicinal chemistry and Chemical biology).

The Program will include:

  • 3 high quality plenary lectures.
  • 9 sessions on key topics in Medicinal Chemistry.
  • An extensive social program to maximise your networking opportunities
  • Poster session and an exhibition.

The ACSMEDI|EFMC Medicinal Chemistry Frontiers Meeting attracts a highly targeted audience composed of experts, researchers and early career trainees in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, and early toxicology.

Session Topics

Enabling Chemistries for Chemical Biology Research
Chair: Prof. Daniel Harki, University of Minnesota, US

Advances in Targeted Protein Degradation
Chair: Prof. Terry Moore, University of Illinois, US

A Focus on Early Career Investigators
Chair: Dr Melissa Grenier-Davies, GlaxoSmithKline, US

Chemical Modulation of RNA
Chair: Dr Darby Schmidt, Sonata Therapeutics, US

Computational Approaches to Identify and Target Cryptic and Allosteric Pockets
Chair: Dr Malin Lemurell, AstraZeneca, SE

Drug Targets in GPCR Signalling
Chair: Prof. György Keseru, Research Centre for Natural Sciences (RCNS), HU

Getting Out of the Starting Block: New Hit Finding and Chemotype Advancement Methods
Chair: Dr Carolyn Dzierba, BMS, US

Organic Synthesis Impacting Medicinal Chemistry & Chemical Biology
Chair: Prof. Rui Moreira, University of Lisbon, PT

Proximity-inducing Molecules and their Therapeutic Applications
Chair: Dr Amit Choudhary, Broad Institute, US

We look forward meeting you in Boston! 

The Organizing Committee 

June 10-13, 2019Krakow, Poland

This biennial meeting is a key symposium in its field with traditionally around 300 participants, from industry and academia. The EFMC - ACSMEDI Medicinal Chemistry Frontiers Meeting attracts a highly targeted audience composed of experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. The scientific programme for this meeting will feature a plenary session, followed by sessions covering the latest advances in medicinal chemistry.

The Final Scientific Programme will include:

  • A first-time disclosure by Novartis: The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorder
  • 3 high quality plenary and 19 keynote speakers, covering the latest advances in the main fields of medicinal chemistry.
  • 6 Oral communications selected from the submitted abstracts
  • A session showcasing Pharma Research Highlights in Poland
  • An extensive social programme to maximise your networking opportunities
  • A Poster session and an exhibition.

The following topics will be addressed:

  • Adding AI to the Drug Discovery Tool Box
    Session Chair
    : Carolyn Dzierba (BRISTOL-MYERS SQUIBB, United States)
  • Advances in Protein Degradation Technologies
    Session Chair
    : Daniel Harki (UNIVERSITY OF MINNESOTA, United States)
  • Chemical Biology Tools & Target Engagement Technologies
    Session Chair
  • Genomics in Drug Discovery : Roles for Chemistry
    Session Chair
    : Terry Moore (UNIVERSITY OF ILLINOIS, United States)
  • GPCRs : a Discovery Powerhouse
    Session Chair
  • Matrix Metallo-Proteinases
    Session Chair
    : Krzysztof Józwiak (MEDICAL UNIVERSITY OF LUBLIN, Poland)
  • Multi-Targeted Drugs
    Session Chair
  • Opioid, Pain, Endo-Cannabinoid
    Session Chair
    : Katarzyna Kiec-Kononowicz (JAGIELLONIAN UNIVERSITY, Poland)
  • Targeted Covalent Inhibitors
    Session Chair
    : Anders Karlén (UPPSALA UNIVERSITY, Sweden)
Organised by:
  • European Federation for Medicinal Chemistry and Chemical Biology (EFMC)
  • Polish Society of Medicinal Chemistry (Poland)

June 25-28, 2017Philadelphia (Sheraton Downtown), USA

ACSMEDI-EFMC Frontiers 2017 Symposium is the sixth in the series initiated in Siena, Italy in 2007 and continued in Barcelona, Spain in 2009, Stockholm, Sweden in 2011, San Francisco, CA in 2013 and Antwerp, Belgium in 2015. The meeting is co-organized by the European Federation of Medicinal Chemistry and the American Chemical Society Division of Medicinal Chemistry. It is intended to bring scientists working in the medicinal chemistry field together in order to share new and exciting results and we encourage attendees to bring poster presentations. Philadelphia provides a picturesque backdrop for this exciting conference, and we know you will have a scientifically rewarding and enjoyable stay.

Frontiers 2017 will take place in the Sheraton Philadelphia Downtown Hotel, located at 201 N. 17th Street St., located in the heart of Philadelphia. The Sheraton Philadelphia Downtown is in close proximity to historic Philadelphia, the Liberty Bell, the Reading Terminal Market and the Franklin Institute, making it an ideal location to enjoy the city, and to experience the latest research in medicinal chemistry.


  • Douglas Beshore, Merck
  • David Chenoweth,University of Pennsylvania
  • Emily Cherney, Bristol-Myers Squibb
  • Craig Crews, Yale University
  • Andrew Degnan, Bristol-Myers Squibb
  • Robert Glen , University of Cambridge
  • Phillip Harris, GlaxoSmithKline USA
  • Thomas Hermann, University of California at San Diego
  • Michael Jung, University of California at Los Angeles
  • György Miklós Keseru, Hungarian Academy of Sciences
  • Andreas Linkermann, Universitätlinikum Carl Gustav Carus
  • Jing Liu, Mount Sinai Research
  • Christa E. Müller, University of Bonn
  • Snahel Patel, Genentech
  • Philip Pitis, Trevana Pharmaceuticals
  • Barry Potter, Oxford University
  • Hasane Ratni, Roche
  • Dustin Siegel, Gilead
  • Michael Sofia, Arbutus
  • Dai-Shi Su, GlaxoSmithKline USA
  • Peter Vandenabeele, Ghent University
  • Koen Vandyck, Johnson and Johnson
  • Eddy Yue, Incyte

September 14-16, 2015Antwerp, Belgium

The Frontiers in Medicinal Chemistry symposium is co-organised on a biennial basis, as a collaboration between the ACS (American Chemical Society) and the EFMC (European Federation for Medicinal Chemistry).

Frontiers in Medicinal Chemistry 2015 will be jointly organised by EFMC, ACS and the local Dutch and Belgian organisers: the Medicinal and Bioorganic Chemistry Division of the Royal Flemish Chemical Society (KVCV, Belgium), the Société Royale de Chimie (SRC, Belgium), and the Section Medicinal Chemistry of the Royal Netherlands Chemical Society (KNCV, The Netherlands).

Session topic areas included:

• Molecular Chaperones and their Therapeutic Potential
• Unexplored Chemical Space: Experiences from the European Lead Factory and the NIH Molecular Libraries Programme
• Emerging Advances in GPCR Research
• Emerging Topics
• Non-Small Molecules
• Novel Strategies for Anti-Thrombotic Therapy
• Kinetics and Thermodynamics of Ligand Binding
• Rational Design of Non-Oral Drugs
• Academic Drug Discovery

Organised by:
  • Division Medicinal Chemistry & Chemical Biology, Royal Netherlands Chemical Society (KNCV-MCCB) (The Netherlands)
  • Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV) (Belgium)
  • Société Royale de Chimie (SRC), Medicinal Chemistry Division (Belgium)

June 23-26, 2013 San Francisco, USA

Co-organised by the European Federation for Medicinal Chemistry and the Division of Medicinal Chemistry of ACS.

Frontiers 2013 took place in the historic Fairmont Hotel, located at 950 Mason St. on Nob Hill, in the heart of San Francisco. Central to the Financial District, Union Square, the Embarcadero and Fisherman's Wharf, the Fairmont Hotel is located at the only spot in San Francisco where each of the City's cable car lines meet. 
The scientific program for Frontiers 2013 featured a plenary session, followed by sessions covering the latest advances in medicinal chemistry.

Session topic areas included:
• Antiviral Drug Design
• Advances in the Treatment of Inflammation
• Imaging, Biomarkers & Translational Research
• Oncology
• Antibody/Drug Conjugates
• Molecular Modeling and Structure-Based Design
• Emerging Topics

June 19-21, 2011Stockholm, Sweden

The Meeting has been co-organized by the European Federation for Medicinal Chemistry, the Division of Medicinal Chemistry of ACS and the Swedish Academy of Pharmaceutical Sciences. It brought together speakers from Scandinavia/Europe and USA that shared exciting new results and first time disclosures in several areas of drug discovery.

Topics included:
• ADME Profiling
• Cancer and Epigenetics
• Case Studies and Emerging Targets
• Chemical Neuroscience
• GPCR´s
• Protein-Protein Interactions
• Structure Based Ligand Design

Organised by:
  • Swedish Pharmaceutical Society (Sweden)

October 4-6, 2009Barcelona, Spain

Under the theme of “Emerging Targets, Novel Candidates and Innovative Strategies”, this three-day international meeting will bring together medicinal chemists and related scientists in order to share exciting new results and first-time disclosures in various areas of drug discovery and development, including cancer, infectious diseases, CNS, inflammation, pain and metabolic disease. Twenty-three internationally recognized plenary speakers will present lectures with a focus on emerging targets, novel drug candidates and new strategies and technologies. Furthermore, poster sessions will help to strengthen ties between scientists in an environment that will foster interaction and discussion.

October 7-9, 2007Siena, Italy

This 3 day international brought together medicinal chemists from the US and Italy to share exciting new results in central nervous system and oncology medicinal chemistry presented by leading academic and industrial researchers. These therapeutic areas are a special strength in Italy, and complements interest in US-based drug discovery research. Substantial progress is being made in the medicinal chemistry of these fields, and will be reflected in the scientific program. There were ample interactive opportunities in scenic Siena for attendees to explore collaborative research possibilities.